News

April 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies

11/04/11

Regenera Pharma received the final report of its safety study in mini-pigs and is moving to human studies
Toxicity profile confirmed the safety of RPh201 at intended treatment doses, as well as at much higher dose levels. The Toxicological study conducted in mini-pigs for three months have not identified any drug-related side effects.
A battery of genotoxicity studies also revealed no abnormal effects.